Duan-Yong Liu

Prof. Duan-Yong Liu

Jiangxi University of Traditional Chinese Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in European Journal of Pharmacology
Verified
Journal Article
Open access
JLJian Long
Jian Long
XLXue-Ke Liu
Xue-Ke Liu
ZKZeng-Ping Kang
Zeng-Ping Kang
MWMeng-Xue Wang
Meng-Xue Wang
HZHai-Mei Zhao
Hai-Mei Zhao
YZYoubao Zhong
Youbao Zhong
Aberrant M1/M2 macrophage polarization and dysbiosis are involved in the pathogenesis of ulcerative colitis (UC). Ginsenoside Rg1 exhibits optimal immunomodulatory and anti-inflammatory effects in treating UC of humans and animals, but the action mechanism through the regulation of M1/M2 macrophage polarization and intestinal flora composition remain unclear. Here, experimental colitis was induced in BALB/c mice using dextran sulfate sodium, and Rock1 inhibitor Y27632 was used to explore the action mechanism of ginsenoside Rg1. Following treatment with ginsenoside Rg1 (200 mg/kg/day) and Y27632 (10 mg/kg/day) for 14 consecutive days, the rate of change in mouse body weight, mouse final weight, colonic weight, colonic length, colonic weight index and pathological damage scores of colitis mice were effectively improved, accompanied by less ulcer formation and inflammatory cell infiltration, lower levels of interleukin (IL)-6, IL-33, chemokine (C-C motif) ligand 2 (CCL-2), tumor necrosis factor alpha (TNF-α), and higher IL-4 and IL-10. Importantly, ginsenoside Rg1 and Y27632 significantly down-regulated CD11b+F4/80+, CD11b+F4/80+Tim-1+ and CD11b+F4/80+TLR4+ macrophages, and CD11b+F4/80+iNOS+ M1 macrophages, and significantly up-regulated CD11b+F4/80+CD206+ and CD11b+F4/80+CD163+ M2 macrophages in colitis mice; concomitantly, ginsenoside Rg1 improved the diversity of colonic microbiota and regulated Lachnospiraceae, Staphylococcus, Bacteroide and Ruminococcaceae_UCG_014 at genus level in colitis mice, but the flora regulated by Y27632 was not identical to it. Moreover, ginsenoside Rg1 and Y27632 down-regulated the protein levels of Rock1, RhoA and Nogo-B in colitis mice. These results suggested that ginsenoside Rg1 and Y27632 ameliorated colitis by regulating M1/M2 macrophage polarization and microbiota composition, associated with inhibition of the Nogo-B/RhoA signaling pathway.

25 November 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HZHai-Mei Zhao
Hai-Mei Zhao
RXRong Xu
Rong Xu
XHXiao-Ying Huang
Xiao-Ying Huang
SCShao-Min Cheng
Shao-Min Cheng
MHMin-Fang Huang
Min-Fang Huang
DLDuan-Yong Liu
Duan-Yong Liu
Dendritic cells (DCs) play a pivotal role as initiators in the pathogenesis of inflammatory bowel disease and are regulated by the JAK/STAT/SOCS signaling pathway. As a potent anti-inflammatory compound, curcumin represents a viable treatment alternative or adjunctive therapy in the management of chronic inflammatory bowel disease (IBD). The mechanism of curcumin treated IBD on DCs is not completely understood. In the present study, we explored the mechanism of curcumin treated experimental colitis by observing activation of DCs via JAK/STAT/SOCS signaling pathway in colitis mice. Experimental colitis was induced by 2, 4, 6-trinitrobenzene sulfonic acid (TNBS). After 7 days treatment with curcumin, its therapeutic effect was verified by decreased colonic weight, histological scores and remitting pathological injury. Meanwhile, the levels of major histocompatibility complex class II (MHC-II) and DC costimulatory molecules (CD83, CD28, B7-DC, CD40, CD40 L and TLR2) were inhibited and followed the up-regulated levels of IL-4, IL-10 and IFN-γ, and down-regulated GM-CSF, IL-12p70, IL-15, IL-23 and TGF-β1. A key finding was that the phosphorylation of the 3 members (JAK2, STAT3 and STAT6) of the JAK/STAT/SOCS signaling pathway was inhibited, and the 3 downstream proteins (SOCS1, SOCS and PIAS3) from this pathway were highly expressed. In conclusion, curcumin suppressed the activation of DCs by modulating the JAK/STAT/SOCS signaling pathway to restore immunologic balance to effectively treat experimental colitis.

19 June 2022 in Phytomedicine
Verified
Journal Article
Closed access
YZYoubao Zhong
Youbao Zhong
WLWenjun Liu
Wenjun Liu
YXYanxia Xiong
Yanxia Xiong
YLYingmeng Li
Yingmeng Li
QWQi Wan
Qi Wan
DLDuan-Yong Liu
Duan-Yong Liu

1 August 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYoubao Zhong
Youbao Zhong
QXQiuping Xiao
Qiuping Xiao
ZKZengping Kang
Zengping Kang
JHJiaqi Huang
Jiaqi Huang
WGWei Ge
Wei Ge
DLDuan-Yong Liu
Duan-Yong Liu

2 March 2022 in Phytotherapy Research
Verified
Journal Article
Open access
QXQiu‐Ping Xiao
Qiu‐Ping Xiao
YZYoubao Zhong
Youbao Zhong
ZKZeng‐Ping Kang
Zeng‐Ping Kang
JHJia‐Qi Huang
Jia‐Qi Huang
WFWei‐Yan Fang
Wei‐Yan Fang
DLDuan-Yong Liu
Duan-Yong Liu
Diabetes mellitus (DM) is one of the most common complications in patients with ulcerative colitis (UC). Curcumin has a wide range of bioactive and pharmacological properties and is commonly used as an adjunct to the treatment of UC and DM. However, the role of curcumin in UC complicated by DM has not been elucidated. Therefore, this study was conducted to construct a model of UC complicating diabetes by inducing UC in DB mice (spontaneously diabetic) with dextran sodium sulfate. In this study, curcumin (100 mg/kg/day) significantly improved the symptoms of diabetes complicated by UC, with a lower insulin level, heavier weight, longer and lighter colons, fewer mucosal ulcers and less inflammatory cell infiltration. Moreover, compared to untreated DB mice with colitis, curcumin‐treated mice showed weaker Th17 responses and stronger Treg responses. In addition, curcumin regulated the diversity and relative abundance of intestinal microbiota in mice with UC complicated by DM at the phylum, class, order, family and genus levels. Collectively, curcumin effectively alleviated colitis in mice with type 2 diabetes mellitus by restoring the homeostasis of Th17/Treg and improving the composition of the intestinal microbiota

19 January 2021 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
ZKZengping Kang
Zengping Kang
YZYoubao Zhonga
Youbao Zhonga
TWTiantian Wu
Tiantian Wu
JHJiaqi Huang
Jiaqi Huang
HZHai-Mei Zhao
Hai-Mei Zhao
DLDuan-Yong Liu
Duan-Yong Liu
Inflammatory bowel disease (IBD) is an autoimmune disease mediated by immune disorder and termed as one of the most refractory diseases by the Word Health Organization. Its morbidity has increased steadily over the past half century worldwide. Environmental, genetic, infectious, and immune factors are integral to the pathogenesis of IBD. Commonly known as the king of herbs, ginseng has been consumed in many countries for the past 2000 years. Its active ingredient ginsenosides, as the most prominent saponins of ginseng, have a wide range of pharmacological effects. Recent studies have confirmed that the active components of Panax ginseng have anti-inflammatory and immunomodulatory effects on IBD, including regulating the balance of immune cells, inhibiting the expression of cytokines, as well as activating Toll-like receptor 4, Nuclear factor-kappa B (NF-κB), nucleotide-binding oligomerization domain-like receptor (NLRP), mitogen-activated protein kinase signaling, and so on. Accumulated evidence indicates that ginsenosides may serve as a potential novel therapeutic drug or health product additive in IBD prevention and treatment in the future.